MX360189B - Terapia de combinacion para el tratamiento de glioblastoma. - Google Patents
Terapia de combinacion para el tratamiento de glioblastoma.Info
- Publication number
- MX360189B MX360189B MX2015001627A MX2015001627A MX360189B MX 360189 B MX360189 B MX 360189B MX 2015001627 A MX2015001627 A MX 2015001627A MX 2015001627 A MX2015001627 A MX 2015001627A MX 360189 B MX360189 B MX 360189B
- Authority
- MX
- Mexico
- Prior art keywords
- glioblastoma
- treatment
- combination therapy
- patient
- therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oncology (AREA)
Abstract
La presente invención se refiere a métodos para tratar a un paciente diagnosticado con glioblastoma, el cual comprende administrar al paciente una terapia que consiste de una cantidad efectiva de un anticuerpo anti-VEGF y un producto quimioterapéutico.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261680672P | 2012-08-07 | 2012-08-07 | |
US201261714438P | 2012-10-16 | 2012-10-16 | |
US201361760763P | 2013-02-05 | 2013-02-05 | |
PCT/US2013/053841 WO2014025813A1 (en) | 2012-08-07 | 2013-08-06 | Combination therapy for the treatment of glioblastoma |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015001627A MX2015001627A (es) | 2015-06-23 |
MX360189B true MX360189B (es) | 2018-10-24 |
Family
ID=48985869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015001627A MX360189B (es) | 2012-08-07 | 2013-08-06 | Terapia de combinacion para el tratamiento de glioblastoma. |
Country Status (15)
Country | Link |
---|---|
US (2) | US20150148585A1 (es) |
EP (2) | EP3446709A1 (es) |
JP (4) | JP6464085B2 (es) |
KR (3) | KR20150038593A (es) |
CN (1) | CN104507498A (es) |
AU (3) | AU2013299724A1 (es) |
BR (1) | BR112015002681A2 (es) |
CA (1) | CA2880767A1 (es) |
HK (1) | HK1204993A1 (es) |
IL (2) | IL237028B (es) |
MX (1) | MX360189B (es) |
RU (1) | RU2015104001A (es) |
SG (1) | SG11201500903XA (es) |
WO (1) | WO2014025813A1 (es) |
ZA (1) | ZA201500811B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102158924B1 (ko) | 2013-03-15 | 2020-09-22 | 제넨테크, 인크. | Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법 |
US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
US10617755B2 (en) * | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
RU2692248C2 (ru) * | 2014-02-14 | 2019-06-24 | Макродженикс, Инк. | Улучшенные способы лечения васкуляризированных злокачественных опухолей |
JP6983511B2 (ja) | 2014-04-25 | 2021-12-17 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 脳中の転移乳癌および他の癌を処置するための方法および組成物 |
WO2015171747A1 (en) * | 2014-05-07 | 2015-11-12 | Medimmune, Llc | Methods of using anti-ang2 antibodies |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
EP3166974A1 (en) | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
CN106460067A (zh) * | 2014-07-14 | 2017-02-22 | 豪夫迈·罗氏有限公司 | 诊断方法和用于治疗成胶质细胞瘤的组合物 |
SG11201805420SA (en) | 2015-12-30 | 2018-07-30 | Kodiak Sciences Inc | Antibodies and conjugates thereof |
CA3067035A1 (en) | 2017-06-12 | 2018-12-20 | Agios Pharmaceuticals, Inc. | Methods of treating brain tumors using combination therapy |
MX2019014934A (es) | 2017-06-12 | 2022-06-28 | Agios Pharmaceuticals Inc | Combinación de vorasidenib con radiación y/o agentes adicionales para tratar gliomas. |
SG11202008242XA (en) | 2018-03-02 | 2020-09-29 | Kodiak Sciences Inc | Il-6 antibodies and fusion constructs and conjugates thereof |
CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
HU225646B1 (en) | 1992-10-28 | 2007-05-29 | Genentech Inc | Hvegf receptors as vascular endothelial cell growth factor antagonists |
US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
BR9609743A (pt) | 1995-07-27 | 1999-03-02 | Genentech Inc | Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
CA2286330C (en) | 1997-04-07 | 2008-06-10 | Genentech, Inc. | Anti-vegf antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
EP2338915A3 (en) | 1997-04-07 | 2011-10-12 | Genentech, Inc. | Anti-VEGF antibodies |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
JP4460155B2 (ja) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
KR20160014775A (ko) | 2003-05-30 | 2016-02-11 | 제넨테크, 인크. | 항-vegf 항체를 사용한 치료 |
WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
JP5128935B2 (ja) | 2004-03-31 | 2013-01-23 | ジェネンテック, インコーポレイテッド | ヒト化抗TGF−β抗体 |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
US8679490B2 (en) | 2005-11-07 | 2014-03-25 | Genentech, Inc. | Binding polypeptides with diversified and consensus VH/VL hypervariable sequences |
EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
AU2007249408A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
KR20120096401A (ko) * | 2009-04-20 | 2012-08-30 | 제넨테크, 인크. | 아주반트 암 요법 |
KR20180028561A (ko) * | 2010-02-23 | 2018-03-16 | 제넨테크, 인크. | 난소암의 치료를 위한 항혈관신생 요법 |
ES2930809T3 (es) * | 2010-08-24 | 2022-12-22 | Univ Pittsburgh Commonwealth Sys Higher Education | Vacunas contra el cáncer cerebral basadas en el péptido receptor de interleucina-13 alfa 2 |
US20120114638A1 (en) * | 2010-11-08 | 2012-05-10 | John Boylan | Combination therapy |
-
2013
- 2013-08-06 CN CN201380040940.7A patent/CN104507498A/zh active Pending
- 2013-08-06 RU RU2015104001A patent/RU2015104001A/ru not_active Application Discontinuation
- 2013-08-06 EP EP18178511.4A patent/EP3446709A1/en not_active Withdrawn
- 2013-08-06 JP JP2015526648A patent/JP6464085B2/ja active Active
- 2013-08-06 WO PCT/US2013/053841 patent/WO2014025813A1/en active Application Filing
- 2013-08-06 MX MX2015001627A patent/MX360189B/es active IP Right Grant
- 2013-08-06 BR BR112015002681A patent/BR112015002681A2/pt not_active Application Discontinuation
- 2013-08-06 CA CA2880767A patent/CA2880767A1/en not_active Abandoned
- 2013-08-06 SG SG11201500903XA patent/SG11201500903XA/en unknown
- 2013-08-06 EP EP13748450.7A patent/EP2882454B1/en not_active Revoked
- 2013-08-06 KR KR20157005660A patent/KR20150038593A/ko active Application Filing
- 2013-08-06 KR KR1020197020608A patent/KR20190088571A/ko not_active Application Discontinuation
- 2013-08-06 AU AU2013299724A patent/AU2013299724A1/en not_active Abandoned
- 2013-08-06 KR KR1020187002046A patent/KR20180011356A/ko not_active Application Discontinuation
-
2015
- 2015-02-01 IL IL237028A patent/IL237028B/en active IP Right Grant
- 2015-02-04 ZA ZA2015/00811A patent/ZA201500811B/en unknown
- 2015-02-06 US US14/616,505 patent/US20150148585A1/en not_active Abandoned
- 2015-06-23 HK HK15105936.9A patent/HK1204993A1/xx unknown
-
2016
- 2016-10-13 AU AU2016244262A patent/AU2016244262B2/en not_active Ceased
-
2017
- 2017-06-30 JP JP2017128609A patent/JP2018008946A/ja not_active Withdrawn
-
2018
- 2018-10-23 AU AU2018253461A patent/AU2018253461A1/en not_active Abandoned
- 2018-12-12 IL IL263661A patent/IL263661A/en unknown
-
2019
- 2019-04-18 JP JP2019079205A patent/JP2019147812A/ja active Pending
- 2019-04-29 US US16/397,104 patent/US20200086139A1/en not_active Abandoned
-
2021
- 2021-05-06 JP JP2021078365A patent/JP2021138704A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP6464085B2 (ja) | 2019-02-06 |
IL263661A (en) | 2019-01-31 |
AU2018253461A1 (en) | 2018-11-15 |
KR20150038593A (ko) | 2015-04-08 |
ZA201500811B (en) | 2016-10-26 |
AU2016244262B2 (en) | 2018-07-26 |
MX2015001627A (es) | 2015-06-23 |
KR20180011356A (ko) | 2018-01-31 |
IL237028B (en) | 2019-03-31 |
HK1204993A1 (en) | 2015-12-11 |
AU2016244262A1 (en) | 2016-11-03 |
JP2019147812A (ja) | 2019-09-05 |
JP2021138704A (ja) | 2021-09-16 |
US20150148585A1 (en) | 2015-05-28 |
US20200086139A1 (en) | 2020-03-19 |
CA2880767A1 (en) | 2014-02-13 |
EP3446709A1 (en) | 2019-02-27 |
RU2015104001A (ru) | 2016-09-27 |
SG11201500903XA (en) | 2015-03-30 |
EP2882454A1 (en) | 2015-06-17 |
CN104507498A (zh) | 2015-04-08 |
JP2015525798A (ja) | 2015-09-07 |
AU2013299724A1 (en) | 2015-02-26 |
KR20190088571A (ko) | 2019-07-26 |
BR112015002681A2 (pt) | 2018-08-28 |
EP2882454B1 (en) | 2018-10-10 |
WO2014025813A1 (en) | 2014-02-13 |
JP2018008946A (ja) | 2018-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016002645A (es) | Tratamiento combinado para tratar el glioblastoma. | |
MX360189B (es) | Terapia de combinacion para el tratamiento de glioblastoma. | |
HK1247567A1 (zh) | 用於治療癌症的涉及針對密蛋白18.2之抗體的聯合治療 | |
MX2021010672A (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer. | |
MX2020011783A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
MX2015002947A (es) | Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo. | |
DK3791896T3 (da) | Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling | |
PH12014501543A1 (en) | Combination therapy for the treatment of ovarian cancer | |
PH12015500246A1 (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
PL3254695T3 (pl) | Terapia skojarzona obejmująca przeciwciała przeciwko Klaudynie 18.2 do leczenia nowotworu | |
MX2014005726A (es) | Metodo de tratamiento de una enfermedad proliferativa. | |
WO2012106473A8 (en) | Dosing for treatment with anti-egfl7 antibodies | |
NZ745950A (en) | Methods and compositions for treating multiple sclerosis and related disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |